Aeterna Zentaris Inc (AEZS.OQ)
1.56USD
20 Apr 2018
$0.06 (+4.00%)
$1.50
$1.50
$1.56
$1.50
1,882
87,612
$3.75
$0.78
About
Overall
| Beta: | 0.84 |
| Market Cap(Mil.): | $34.19 |
| Shares Outstanding(Mil.): | 16.21 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
BRIEF-Aeterna Zentaris Qtrly Loss Per Share $0.03
* AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS
BRIEF-Aeterna Zentaris Appoints James Clavijo As CFO
* AETERNA ZENTARIS APPOINTS JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER
BRIEF-Aeterna Zentaris Provides Update On Previously Disclosed Class Action Lawsuit
* AETERNA ZENTARIS PROVIDES UPDATE ON PREVIOUSLY DISCLOSED CLASS ACTION LAWSUIT
BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada
* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA
BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore
* AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE
BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris
* DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS
Canada's Aeterna gets FDA approval for growth hormone deficiency test
Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency.
Canada's Aeterna gets FDA approval for growth hormone deficiency test
Dec 20 Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018.
BRIEF-Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency
* AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY
BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER
Competitors
| Price | Chg | |
|---|---|---|
| Merck & Co., Inc. (MRK.N) | $58.83 | +0.19 |
| Pfizer Inc. (PFE.N) | $36.63 | +0.10 |
| Astellas Pharma Inc (4503.T) | ¥1,582 | -10.00 |
| Sanofi SA (SASY.PA) | €65.28 | -0.32 |
| Abbott Laboratories (ABT.N) | $59.19 | -0.69 |
| GlaxoSmithKline Pharmaceuticals Limited (GLAX.NS) | Rs2,431.10 | +45.15 |
| Actavis Inc (WATS.O) | -- | -- |
| Recordati SpA (RECI.MI) | €29.84 | -0.14 |
| Kissei Pharmaceutical Co Ltd (4547.T) | ¥3,015 | +5.00 |
| Novartis AG (NOVN.S) | CHF76.08 | -1.20 |
Estimates